Clinical trials: Hematological Patients
Hematologic Malignancy, Muscle Weakness
Effects of NMES and Exercise in Hematological Cancer
Physical activity levels of adult hematologic cancer patients are deficient. The resulting physical inactivity causes fatigue, muscle loss, and deterioration in physical performance values.
- Trial name
- NCT04755465
- Testing
- Neuromuscular Electrical Stimulation, Structured Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 31 people
- Sponsor
- Acibadem University
Leukemia, Myelodysplastic Syndromes
Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer
RATIONALE: Giving chemotherapy and total-body irradiation before a donor stem cell transplant or a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from…
- Trial name
- NCT00534430
- Testing
- busulfan, cyclosporine, etoposide
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Castrate Resistant Prostate Cancer, NUT Carcinoma
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies
- Conditions
- Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia, Myelofibrosis
- Trial name
- NCT05488548
- Testing
- EP31670
- Where
- 6 sites in United States
- Volunteers
- 75 people
- Sponsor
- Epigenetix, Inc.
Hematologic Neoplasms
Immunological Parameters, Neurocognitive Changes, Activity, & Driving Fitness in Patients Undergoing CAR-T Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy is a promising new treatment that re-programs patient immune cells to target and destroy cancer cells.
- Trial name
- NCT04275154
- Sponsor
- University of Nebraska
Bone Marrow Transplant Complications
Assesment of Upper Egypt Experience in Autologous Bone Marrow Transplantation of Patients With Hematological Malignancies: A Cohor Study
Autologous hematopoietic stem cell transplantation (ASCT) is an important treatment for eligible patients with hematological malignancies, particularly multiple myeloma and relapsed lymphoma.
- Trial name
- NCT07823946
- Volunteers
- 123 people
- Sponsor
- Assiut University
High Risk Hematological Malignancy, Cord Blood Transplant
US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia
Cord blood (CB) transplants are an option for patients lacking an HLA identical donor but are hampered by low cell dose, prolonged aplasia and high transplant related mortality.
- Trial name
- NCT04103879
- Testing
- ECT-001-CB (UM171-Expanded Cord Blood Transplant)
- Where
- 3 sites in United States, Netherlands
- Volunteers
- 30 people
- Sponsor
- ExCellThera inc.
Extrahepatic Portal Vein Obstruction (EHPVO), Thrombophilia
Hematological Disorders in EHPVO Patients
This study focuses on patients who have a condition called extrahepatic portal vein obstruction (EHPVO), where a blood clot blocks the portal vein outside the liver.
- Conditions
- Extrahepatic Portal Vein Obstruction (EHPVO), Thrombophilia, Myeloproliferative Neoplasms (MPN), Antiphospholipid Syndrome (APS)
- Trial name
- EHPVO-HEM (NCT07108023)
- Testing
- No intervention (Observational Study)
- Volunteers
- 115 people
- Sponsor
- Rahab Nady
Relapsed or Refractory Hematological Malignancies
Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies
To define the maximum tolerated dose of oral daily ENMD 2076 in patients with relapsed or refractory hematological malignancies
- Trial name
- NCT00904787
- Testing
- ENMD-2076
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- CASI pharmaceuticals, Inc.
Hematological Cancer
Patient-Reported Outcomes Integrated in the Follow-up of Patients With Hematological Cancer
This study investigates if integration of patient-reported outcomes in the follow-up of patients with newly diagnosed, not curable, chronic hematological cancer changes the number and kind of supportive care interventions.
- Trial name
- NCT03056469
- Testing
- Completion of patient-reported outcome (PRO) questionnaires
- Where
- Denmark
- Volunteers
- 225 people
- Sponsor
- Zealand University Hospital
Hematological Malignancies, Neutropenia
Observational Study Investigating the Response Rate of Itraconazole Injection in Treating Immunocompromised Patients
The purpose of this observational study is to examine the rate at which elevated body temperature (fever) is relieved by an itraconazole injection administrated to patients experiencing neutropenic fever .
- Conditions
- Hematological Malignancies, Neutropenia, Fever
- Trial name
- NCT01060462
- Testing
- Pts. w/ neutropenic fever associated w/ hematologic malignancy
- Volunteers
- 438 people
- Sponsor
- Janssen Korea, Ltd., Korea
Hodgkin's Lymphoma, Lymphoid Leukemia
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Determine the relapse-free, donor lymphocyte infusion (DLI)-free survival in patients receiving the investigational regimen.This is a randomized phase II clinical trial, comparing two different dosing schedules of mycophenolate…
- Conditions
- Hodgkin's Lymphoma, Lymphoid Leukemia, Lymphoma, Leukemia
- Trial name
- NCT02593123
- Testing
- mycophenolate mofetil, Sargramostim, Filgrastim
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Virginia Commonwealth University
Neoplasms, Hematologic Neoplasms
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
This study will collect biological samples for use in research experiments aimed at better understanding the clinical features of certain diseases.
- Conditions
- Neoplasms, Hematologic Neoplasms, Healthy Volunteers
- Trial name
- NCT00071045
- Where
- United States
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL.
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Trial name
- HEM-iSMART D (NCT05658640)
- Testing
- Trametinib, Dexamethasone, Cyclophosphamide
- Where
- 36 sites in Austria, Belgium and 13 more
- Volunteers
- 26 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Acute Leukemias, Chronic Leukemias
Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)
Long-term follow-up studies have demonstrated significant late toxicities of total body irradiation (TBI), which are most marked in children radiated at a young age.
- Conditions
- Acute Leukemias, Chronic Leukemias, Myelodysplastic Syndrome, Juvenile Myelomonocytic Leukemia
- Trial name
- NCT01339988
- Testing
- Busulfan/Cyclophosphamide
- Volunteers
- 10 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Linperlisib, PRCA
Low-Dose Linperlisib Achieves Rapid Hematological Response in a Patient With Pure Red Cell Aplasia and Moderate-to-Severe Renal Insufficiency: A Case Report
This article reports a case of a 70-year-old male patient diagnosed with T-cell large granular lymphocytic leukemia (T-LGLL)-associated pure red cell aplasia (PRCA) complicated by moderate-to-severe renal insufficiency.
- Conditions
- Linperlisib, PRCA, Moderate-to-Severe Renal Insufficiency
- Trial name
- NCT07900282
- Testing
- linperlisib
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Peking Union Medical College Hospital
Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma
Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy
This study evaluates the addition of Atezolizumab to current therapy of Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) for patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) that are not candidates for…
- Conditions
- Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Trial name
- ARGO (NCT03422523)
- Testing
- Atezolizumab, Rituximab, Gemcitabine 1000 mg
- Where
- United Kingdom
- Volunteers
- 53 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Hematologic Diseases
Naturopathic-pharmacological Consultation in Hematology
The goal of this cross-sectional study is to learn about the effect of a naturopathic-pharmacologic consultation in patients with hematologic conditions.
- Trial name
- NCT05982262
- Testing
- Naturopathic-pharmacological consultation
- Where
- Israel
- Volunteers
- 42 people
- Sponsor
- Bnai Zion Medical Center
Hematological Malignancy, Bone Marrow Failure Syndrome
Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation
The purpose of this study is to determine whether Eltrombopag may shorten time to platelet engraftment after allogeneic cord blood transplantation.
- Trial name
- NCT01757145
- Testing
- Eltrombopag
- Where
- 2 sites in Israel
- Volunteers
- 20 people
- Sponsor
- Rabin Medical Center
Hematologic Neoplasms
Mind-body Medicine for Patients With Malignant Hematological Diseases
This randomized controlled trial aims to investigate the effectiveness of a mind-body group program as a supprtivemanagement strategy for fatigue in patients with malignant hematological diseases.
- Trial name
- NCT03735992
- Testing
- Mind-body medicine group program
- Where
- Germany
- Volunteers
- 94 people
- Sponsor
- Universität Duisburg-Essen
Leukemia, Lymphoma
Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies
The purpose of this study is to find out how many irradiated natural killer (NK) cells can be safely given to patients with cancer that has recurred after an autologous stem cell transplant, and to see what effects (good and bad)…
- Conditions
- Leukemia, Lymphoma, Myeloma, Hodgkin's Disease
- Trial name
- NCT00990717
- Testing
- NK-92 cells
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University Health Network, Toronto